Exploratory Phase II Study of Atractylodes lancea (Thunb.) DC. in Advanced-Stage Intrahepatic Cholangiocarcinoma

Le résumé fourni par la source

Objective: The objective of the study was to evaluate the clinical efficacy, safety, immunomodulatory activity, and effects on quality of life (QoL) of a capsule formulation of Atractylodes lancea (Thunb.) DC. Chemistry Manufacturing and Control capsule formulation of standardized extract of A. lancea (CMC-AL) in patients with advanced stage of intrahepatic cholangiocarcinoma (iCCA). Patients and Methods: A total of eligible 48 patients were randomly assigned to one of three groups. Group 1 received a once-daily dose of 1000 mg of CMC-AL in combination with palliative care for 3 months ( n = 16). Group 2 received escalating doses of 1000, 1500, and 2000 mg of CMC-AL, along with palliative care for 3 months ( n = 16). The control group received palliative care alone ( n = 16). All patients were followed up for 4 months. Serum cytokine levels were measured using a bead array, and safety and treatment responses were evaluated according to standard criteria. Results: CMC-AL at both dosage levels was well tolerated. The high-dose regimen (Group 2) significantly improved the patients’ clinical responses and QoL. Furthermore, there was a notable improvement in median total QoL scores compared to the baseline. Serum interleukin-6 levels on day 14 in both Groups 1 and 2 significantly decreased compared to baseline measurements. Conclusions: Results showed a promising role for CMC-AL in the treatment and management of iCCA. The high-dose CMC-AL showed advantages over the low-dose formulation and palliative care alone in enhancing clinical response, minimizing disease progression, improving QoL, and exhibiting immune-stimulatory effects. Therefore, the high-dose regimen could serve as an alternative treatment for iCCA patients who decline chemotherapy.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.